
DocGo (DCGO) Stock Forecast & Price Target
DocGo (DCGO) Analyst Ratings
Bulls say
DocGo is positioned for future growth through their enterprise deal with an online pharmacy and the acquisition of Hicuity Health, which has a profitable virtual care business. While revenue declined in 2Q26, they exceeded our estimates for gross margins and have added resources, such as debt capital, to increase liquidity. With a majority of revenue generated in the United States, there is potential for further expansion into other markets to drive even more growth.
Bears say
DocGo is facing several headwinds, including slower-than-expected cost cuts impacting profitability and potential delays in the licensing process. While the company's recent acquisition of Hicuity Health brought in significant revenue, there are concerns about the sustainability of this growth. Additionally, the company's narrowed revenue guidance and lowered adjusted EBITDA outlook for FY26 also raises concerns about their ability to achieve long-term profitability. There is also the risk of COVID-related uncertainty and the possibility of decreased revenue once testing contracts and vaccine programs wind down. Overall, DocGo's negative outlook is based on these concerns and the company's need to overcome these challenges in order to achieve sustained growth and profitability.
This aggregate rating is based on analysts' research of DocGo and is not a guaranteed prediction by Public.com or investment advice.
DocGo (DCGO) Analyst Forecast & Price Prediction
Start investing in DocGo (DCGO)
Order type
Buy in
Order amount
Est. shares
0 shares